Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-096673
Filing Date
2025-07-17
Accepted
2025-07-17 17:30:04
Documents
2
Period of Report
2025-07-15

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1559
2 EX-24 tcrt-ex24.htm EX-24 18150
  Complete submission text file 0000950170-25-096673.txt   21308
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Issuer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 10026 BROMPTON DRIVE TAMPA FL 33626
Business Address
Jerman Michael Allen (Reporting) CIK: 0001979732 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33038 | Film No.: 251131851